13 results
8-K
EX-2.1
ALT
Altimmune Inc
9 Jul 19
Altimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to Portfolio
7:58am
8-K
EX-2.1
ALT
Altimmune Inc
17 Aug 17
Altimmune Announces $14.7 Million Series B Preferred Stock Offering
12:00am
8-K
EX-2.1
ALT
Altimmune Inc
29 Mar 17
Entry into a Material Definitive Agreement
12:00am
425
EX-2.1
ALT
Altimmune Inc
29 Mar 17
Business combination disclosure
12:00am
425
EX-2.1
ALT
Altimmune Inc
19 Jan 17
Business combination disclosure
12:00am
8-K
EX-2.1
973l3sel8i 91i
19 Jan 17
PharmAthene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious Diseases
12:00am
8-K
EX-2.1
givj8h kteigjbwyktxt
2 Dec 13
Termination of a Material Definitive Agreement
12:00am
425
EX-2.1
ldm6vwpx
1 Aug 13
Business combination disclosure
12:00am
8-K
EX-2.1
ufak03lu
1 Aug 13
Entry into a Material Definitive Agreement
12:00am
8-K
EX-2.1
u4m6cmi7
8 Apr 08
Pharmathene Closes Acquisition of
12:00am
8-K
EX-2.1
loj vjk8kd
26 Mar 08
Entry into a Material Definitive Agreement
12:00am
DEFA14A
EX-2.1
wsdixuoqirdud2cb9ha1
23 Jan 07
Additional proxy soliciting materials
12:00am
8-K
EX-2.1
6ahtdtozqmsxw mvuh
22 Jan 07
Announce Definitive Merger Agreement
12:00am
- Prev
- 1
- Next